Durvalumab Combined with BCG Significantly Improves Disease-Free Survival in High-Risk Bladder Cancer -

Durvalumab Combined with BCG Significantly Improves Disease-Free Survival in High-Risk Bladder Cancer

Lenvatinib/Everolimus Combo Boosts PFS in Pretreated Clear Cell RCC

A phase 2 study presented at the 2025 ESMO Congress compared lenvatinib plus everolimus with cabozantinib in patients with metastatic clear cell renal cell carcinoma whose disease progressed after PD-1 immunotherapy. The study included 86 patients, most of whom had previously received nivolumab or ipilimumab. The combination of lenvatinib and everolimus significantly improved progression-free survival,

Lenvatinib/Everolimus Combo Boosts PFS in Pretreated Clear Cell RCC Read More »

Dato-DXd Plus Rilvegostomig Achieves High Response Rates in Advanced Urothelial Cancer Trial

Clinical Trails / li001

A new combination therapy for advanced urothelial cancer shows promising results, according to the Phase 2 TROPION-PanTumor03 trial. Datopotamab deruxtecan (Dato-DXd), a TROP2-targeted antibody-drug conjugate, was combined with rilvegostomig, a bispecific antibody against PD-1 and TIGIT, to enhance antitumor activity. In cisplatin-ineligible, first-line patients (n=22), the confirmed objective response rate (ORR) was 68.2%, with a

Dato-DXd Plus Rilvegostomig Achieves High Response Rates in Advanced Urothelial Cancer Trial Read More »

Scientists Turn ‘Cold’ Tumors ‘Hot’ to Prevent Cancer Recurrence

Research Advances / li001

Scientists have shown that boosting the body’s natural immune defenses can prevent cancer recurrence and improve survival in mouse models of multiple cancers. Published in Nature Immunology, the study demonstrates how transforming “immune-cold” tumors—which typically evade immune detection—into “immune-hot” ones can make them more responsive to immune attack. The researchers achieved this transformation by inducing

Scientists Turn ‘Cold’ Tumors ‘Hot’ to Prevent Cancer Recurrence Read More »

Bile Acids: The Missing Link in Liver Cancer Immunotherapy Failure

Research Advances / li001

Immunotherapy has revolutionized cancer treatment but remains less effective against liver cancer, whose incidence has nearly tripled in recent years. Scientists discovered that certain bile acids produced by the liver can suppress cancer-fighting T cells. Harmful bile acids such as LCA and TCDCA cause stress and oxidative damage to T cells, weakening their ability to

Bile Acids: The Missing Link in Liver Cancer Immunotherapy Failure Read More »

New DNA-Protecting Protein Could Hold Key to Destroying Cancer Cells

Research Advances / li001

Researchers have identified KCTD10 as a key “traffic controller” for DNA, coordinating the essential processes of replication and transcription to maintain genomic stability. During cell division, replication machinery rapidly duplicates DNA, while transcription machinery reads it to produce RNA. Collisions between these processes can cause DNA damage, double-strand breaks, and mutations that drive cancer. KCTD10

New DNA-Protecting Protein Could Hold Key to Destroying Cancer Cells Read More »

Dual Immunotherapy Approach Eradicates Liver Metastases in Advanced Colon Cancer

Immunotherapy / li001

Advanced colon cancer is a growing cause of cancer-related death among young American men, particularly when it spreads to the liver. Liver metastases are highly resistant to current immunotherapies and often recur even after surgery, creating a critical need for new treatment strategies. A recent study identified a novel dual-immunotherapy approach that reprograms the liver

Dual Immunotherapy Approach Eradicates Liver Metastases in Advanced Colon Cancer Read More »

Calquence Triplet Achieves 92% Complete Response Rate in Frontline Follicular Lymphoma

Treatment / li001

A phase 2 study published in Nature Communications (NCT04404088) showed that the frontline, chemotherapy-free combination of acalabrutinib (Calquence), lenalidomide (Revlimid), and rituximab (Rituxan) was both safe and effective for patients with advanced-stage, high-tumor-burden follicular lymphoma. Among 24 patients with a median follow-up of 43 months, the best complete response rate reached 92% after just six treatment

Calquence Triplet Achieves 92% Complete Response Rate in Frontline Follicular Lymphoma Read More »

Gene Therapy Destroys KSHV-Linked Cancer Cells

Precision Medicine / li001

A new, highly targeted gene therapy developed by UC Davis scientists, shows promise for treating cancers caused by the Kaposi’s sarcoma-associated herpesvirus (KSHV), such as Kaposi’s sarcoma. The preclinical study, published in Molecular Therapy Oncology, utilizes a harmless adeno-associated virus (AAV) to deliver a “Trojan horse” gene into KSHV-infected cancer cells. This therapy is activated

Gene Therapy Destroys KSHV-Linked Cancer Cells Read More »

Rucaparib Maintenance Therapy Significantly Extends Survival in Recurrent Endometrial Cancer

Treatment / li001

Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) greatly improved progression-free survival in patients with recurrent or metastatic endometrial cancer after first- or second-line chemotherapy, according to a phase 2 study. Patients receiving rucaparib had a median progression-free survival of 28.1 months compared with 8.7 months for those given a placebo, representing a 55% lower

Rucaparib Maintenance Therapy Significantly Extends Survival in Recurrent Endometrial Cancer Read More »